Vestra Clinics s.r.o.
Welcome,         Profile    Billing    Logout  
 4 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bolouri, Mohammad
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
06/24
03/26
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Active, not recruiting
2/3
225
Canada, US
Piromelatine 20 mg, Neu-P11, Placebo
Neurim Pharmaceuticals Ltd., Syneos Health
Alzheimer's Disease
06/25
06/25
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
SHINE, NCT03507790 / 2022-002326-27: A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Completed
2
153
Europe, US, RoW
CT1812, Study Drug, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA)
Mild to Moderate Alzheimer's Disease
05/24
05/24
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting
2
300
Japan, US
Mevidalen, LY3154207, Placebo
Eli Lilly and Company
Alzheimer Disease
12/25
01/26
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Recruiting
2
282
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
12/26
02/29
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
NCT06750432: PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

Recruiting
1
128
US
PMN310, Placebo
ProMis Neurosciences, Inc
Alzheimer Disease, Early Onset
07/26
12/26
Drake, Ryan
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Checkmark Enrollment initiated in combination with Emgality for episodic migraine
Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine
Completed
4
580
US
Galcanezumab, LY2951742, Rimegepant, Placebo
Eli Lilly and Company
Migraine, Episodic Migraine
05/23
05/23
NCT05156047: A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Completed
3
214
US
Open-label pitolisant, Double-blind placebo, Double-blind pitolisant
Harmony Biosciences, LLC
Idiopathic Hypersomnia
09/23
09/23
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Completed
3
469
Europe, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Sleep Apnea, Obesity
03/24
03/24
NCT06517758: A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.

Recruiting
3
146
Europe, Japan, US, RoW
Iptacopan, Matching Placebo
Novartis Pharmaceuticals
Generalized Myasthenia Gravis
12/26
01/29
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
06/24
03/26
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Completed
2/3
320
US
Buntanetap/Posiphen, Posiphen Tartrate, Placebo
Annovis Bio Inc.
Alzheimer Disease
02/24
02/24
SUVN-G3031, NCT04072380: A Study to Evaluate Safety, and Efficacy of (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

Completed
2
190
Canada, US
SUVN-G3031, Samelisant, Placebo
Suven Life Sciences Limited
Narcolepsy
06/23
06/23
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Active, not recruiting
2
160
Europe, US
Neflamapimod, VX-745, Placebo
EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc
Dementia With Lewy Bodies
08/24
03/25
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
Adamcová, Jitka
No trials found

Download Options